Scientists are making waves with a novel therapy for metastatic colorectal cancer (mCRC) that combines two powerful antibodies–one targeting epidermal growth factor receptor (EGFR), the other programmed cell death 1 (PD-1). This dual treatment aims to supercharge the immune system, showing early signs of improving survival and response rates. For patients with no other treatment options, this breakthrough offers a glimmer of hope, potentially changing the trajectory of their fight against cancer.
